 ADC Therapeutics SA NYSE: ADCT has entered an exclusive license agreement with Mitsubishi Tanabe Pharma Corporation to develop and commercialize Zynlonta loncastuximab tesirine-lpyl for all hematologic and solid tumor indications in Japan. Under the agreement terms, ADC Therapeutics will receive an upfront payment of 30 million and up to an additional 205 million in milestones payments. 